Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 39, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13046-020-01686-9
Keywords
c-Jun; Activator Protein-1; transcriptional regulator; basic leucine zipper; cancer; peptides; protein-protein interaction
Categories
Funding
- Cancer Research UK [A26941]
- Medical Research Council [MR/T028254/1]
- Biotechnology and Biological Sciences Research Council [BB/R017956/1, BB/R017921/1, BB/T018275/1]
- BBSRC [BB/R017956/1, BB/T018275/1, BB/R017921/1] Funding Source: UKRI
Ask authors/readers for more resources
The activator protein-1 (AP-1) family of transcription factors modulate a diverse range of cellular signalling pathways into outputs which can be oncogenic or anti-oncogenic. The transcription of relevant genes is controlled by the cellular context, and in particular by the dimeric composition of AP-1. Here, we describe the evidence linking cJun in particular to a range of cancers. This includes correlative studies of protein levels in patient tumour samples and mechanistic understanding of the role of cJun in cancer cell models. This develops an understanding of cJun as a focal point of cancer-altered signalling which has the potential for therapeutic antagonism. Significant work has produced a range of small molecules and peptides which have been summarised here and categorised according to the binding surface they target within the cJun-DNA complex. We highlight the importance of selectively targeting a single AP-1 family member to antagonise known oncogenic function and avoid antagonism of anti-oncogenic function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available